Regeneron strikes drug pricing deal with Trump, offers hearing-loss therapy free
Regeneron agrees to most favoured nation pricing for Medicaid prescriptions under White House affordability push
Briefing
- •Regeneron has agreed a drug pricing deal with the Trump administration, committing to offer prescriptions at most favoured nation prices.
- •The company will provide its newly FDA-approved hearing-loss therapy at no cost as part of the arrangement.
- •The deal is part of a broader White House push to reduce pharmaceutical costs, particularly within Medicaid.
- •Regeneron is among the first major drug makers to formalise a pricing agreement directly with the Trump administration under this initiative.
Why it matters
- →Regeneron's willingness to accept most favoured nation pricing and provide a therapy at zero cost sets a compliance template that other large-cap biopharma firms will face pressure to match, particularly those with Medicaid-heavy drug portfolios. The deal structure shifts the negotiating baseline: firms that resist will face political exposure, while those that comply absorb direct revenue reductions. Large-molecule biologics companies with Medicaid dependency, including those with recently approved therapies priced above generic levels, face the sharpest margin risk.
- →Regeneron's deal insulates it from the most aggressive executive action on drug pricing while locking in revenue certainty at lower net prices. The managed care sector, particularly UNH and peers, benefits if MFN-linked pricing reduces Medicaid drug spend, as it reduces medical loss ratio pressure for plans with large Medicaid managed care books. UNH's recent beat and raised guidance already reflects improving cost trends; additional pricing containment on the drug side compounds that positive trend for managed care.
Historical Context
- 2020
Trump's first-term MFN executive order directed Medicare drug payments to be tied to international reference prices. It was blocked in court and never implemented, but it established the legal and political architecture that this round of voluntary bilateral agreements is now operationalizing without requiring statutory change.
- 2003
The Medicare Modernization Act prohibited Medicare from directly negotiating drug prices. The Inflation Reduction Act of 2022 partially reversed this for a narrow set of drugs. Voluntary MFN deals with individual manufacturers now circumvent the statutory constraint by making compliance a bilateral commercial arrangement rather than a regulatory mandate.